Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with...
Colt DCS Publishes 2024 Sustainability Highlights Report
Achieved 90% renewable energy procurement across the global estate. Maintained EcoVadis Platinum rating to be placed in the top 1% of assessed companies. Winner of Best Colocation Provider Sustainability Innovation of the Year Award. LONDON, June...
2024 Sustainability Report Showcases Yum China's Consistent Commitment to ESG
SHANGHAI, April 7, 2025 /PRNewswire/ -- Yum China Holdings, Inc. (NYSE: YUMC and HKEX: 9987, "Yum China" or the "Company") today announced that it has published its 2024 Sustainability Report. This report outlines the achievements and ongoing...